首页> 外文期刊>British Journal of Pharmacology >Investigation of the functional role played by the chemokine monocyte chemoattractant protein-1 in interleukin-1-induced murine peritonitis.
【24h】

Investigation of the functional role played by the chemokine monocyte chemoattractant protein-1 in interleukin-1-induced murine peritonitis.

机译:趋化因子单核细胞趋化蛋白-1在白介素1诱导的鼠腹膜炎中的功能作用研究。

获取原文
获取原文并翻译 | 示例
       

摘要

1. Intraperitoneal (i.p.) injection of murine recombinant IL-1beta (mrIL-1beta) produced a dose-dependent (0.5-50 ng) and time-related (0.5-2 h) secretion of murine monocyte chemoattractant protein-1 (mMCP-1; 3-4 ng per cavity) in the lavage fluids. MCP-1 mRNA could also be detected in the cell pellets by reverse transcriptase-polymerase chain reaction (RT-PCR). 2. MCP-1 levels were reduced by more than 90% by co-administration of IL-1 receptor antagonist (10 microg) (n=6, P<0.05). In contrast, an IL-1 mutant with low affinity for IL-1 receptor type I, termed yIL-1betadelta4 (50 ng), produced only a modest release of the chemokine. Treatment of mice with dexamethasone (DEX) (approximately 1 mg kg(-1) s.c.) reduced mrIL-1beta-induced mMCP-1 gene expression (apparent total inhibition) and protein release in the lavage fluids (approximately 40% reduction; n=10; P<0.05). Drastic reductions in the numbers of residential macrophages or mast cells did not modify the levels of mMCP-1 recovered in the lavage fluids. 3. Injection of mrIL-1beta produced neutrophil accumulation into the peritoneal cavities (maximal at 4 h with 1.42+/-0.15 x 10(6) cells per mouse). Co-injection of a specific polyclonal antibody against mMCP-1 reduced this process by more than 50% (n=6; P<0.05). In conclusion, we studied the mechanisms leading to the specific release of the CC chemokine mMCP-1 after in vivo administration of mrIL-1beta.
机译:1.小鼠重组IL-1beta(mrIL-1beta)的腹膜内(ip)注射产生剂量依赖性(0.5-50 ng)和时间相关(0.5-2 h)的鼠单核细胞趋化蛋白1(mMCP- 1;灌洗液中每个腔3-4 ng)。还可以通过逆转录聚合酶链反应(RT-PCR)在细胞沉淀物中检测到MCP-1 mRNA。 2.联合使用IL-1受体拮抗剂(10微克)可使MCP-1水平降低90%以上(n = 6,P <0.05)。相反,对I-1型受体I-1具有低亲和力的IL-1突变体,称为yIL-1betadelta4(50 ng),仅产生适度的趋化因子释放。地塞米松(DEX)(约1 mg kg(-1)sc)对小鼠的治疗降低了mrIL-1beta诱导的mMCP-1基因表达(表观总抑制)和灌洗液中的蛋白质释放(减少了约40%; n = 10; P <0.05)。住宅巨噬细胞或肥大细胞数量的急剧减少并未改变灌洗液中回收的mMCP-1的水平。 3.注射mrIL-1beta产生的中性粒细胞积累进入腹膜腔(每只小鼠在4 h时最大,1.42 +/- 0.15 x 10(6)个细胞)。共注射针对mMCP-1的特异性多克隆抗体可将这一过程减少50%以上(n = 6; P <0.05)。总之,我们研究了体内施用mrIL-1beta后导致CC趋化因子mMCP-1特异性释放的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号